MS CUP

MS CUP

Time to fill it with action!

Multiple Scleroses Coalition to Unleash Power

Following in the successful footsteps of ACT UP (Aids Coalition to Unleash Power)

Who and what we are. MS sufferers who are tired of high drug costs and lack of research for cause and cure.

What we want, action and who we are after, this is only the beginning.

 Wall St pharmaceutical companies: for profiteering from people with MS by charging astronomically high prices for MS medicine, which do cure the disease and the lack of interest in finding a cure.

 The FDA for its for its years-long drug approval process, resulting in the disabilities of thousands due to lack of access to potentially life changing drugs and procedures.

**For now please email me contact info so I can add to petition. Your info will be used for nothing other than this action.** Also looking for others to join with me and help with petition. **

Advertisements

FDA

Code of Federal Regulations]
[Title 21, Volume 1]
[Revised as of April 1, 2015]
[CITE: 21CFR10.30]

This is what the FDA gave me. Not sure how to start. We want a cure, we want action, we want what??

TITLE 21–FOOD AND DRUGS
CHAPTER I–FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER A–GENERAL

PART 10 — ADMINISTRATIVE PRACTICES AND PROCEDURES

Subpart B–General Administrative Procedures

Sec. 10.30 Citizen petition.
(a) This section applies to any petition submitted by a person (including a person who is not a citizen of the United States) except to the extent that other sections of this chapter apply different requirements to a particular matter.

(b) A petition (including any attachments) must be submitted in accordance with the following paragraphs, as applicable:

(1) Electronic submission. Petitions (including any attachments) may be electronically submitted in accordance with paragraph (b)(3) of this section and 10.20 through http://www.regulations.gov at Docket No. FDA 2013-S-0610. It is only necessary to submit one copy.

(2) Mail, delivery services, or other non-electronic submissions. A petition (including any attachments), that is not electronically submitted under paragraph (b)(1) of this section, must be submitted in accordance with paragraph (b)(3) and 10.20 and delivered to this address: Division of Dockets Management, Department of Health and Human Services, Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. It is only necessary to submit two copies.

(3) Petition format. A petition submitted under paragraphs (b)(1) or (b)(2) of this section must be in accordance with 10.20 and in the following format:

Citizen Petition

______________________________________________________________Date:

The undersigned submits this petition under __ (relevant statutory sections, if known) of the __ (Federal Food, Drug, and Cosmetic Act or the Public Health Service Act or any other statutory provision for which authority has been delegated to the Commissioner of Food and Drugs) to request the Commissioner of Food and Drugs to__ (issue, amend, or revoke a regulation or order or take or refrain from taking any other form of administrative action).

A. Action Requested

((1) If the petition requests the Commissioner to issue, amend, or revoke a regulation, the exact wording of the existing regulation (if any) and the proposed regulation or amendment requested.)

((2) If the petition requests the Commissioner to issue, amend, or revoke an order, a copy of the exact wording of the citation to the existing order (if any) and the exact wording requested for the proposed order.)

((3) If the petition requests the Commissioner to take or refrain from taking any other form of administrative action, the specific action or relief requested.)

B. Statement of Grounds

(A full statement, in a well-organized format, of the factual and legal grounds on which the petitioner relies, including all relevant information and views on which the petitioner relies, as well as representative information known to the petitioner which is unfavorable to the petitioner’s position.)

C. Environmental Impact

(A) Claim for categorical exclusion under 25.30, 25.31, 25.32, 25.33, or 25.34 of this chapter or an environmental assessment under 25.40 of this chapter.)

D. Economic Impact

(The following information is to be submitted only when requested by the Commissioner following review of the petition: A statement of the effect of requested action on: (1) Cost (and price) increases to industry, government, and consumers; (2) productivity of wage earners, businesses, or government; (3) competition; (4) supplies of important materials, products, or services; (5) employment; and (6) energy supply or demand.)

E. Certification

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

______________________________________________________________(Signature)

______________________________________________________________(Name of petitioner)

______________________________________________________________(Mailing address)

______________________________________________________________(Telephone number)

(c) A petition which appears to meet the requirements of paragraph (b)(3) of this section and 10.20 will be filed by the Division of Dockets Management with the date of filing and assigned a unique docket number. The unique docket number identifies the docket file established by the Division of Dockets Management for all submissions relating to the petition, as provided in this part. Subsequent submissions relating to the matter must refer to the assigned docket number assigned in this paragraph and will be filed in the established docket file. Related petitions may be filed together and given the same docket number. The Division of Dockets Management will promptly notify the petitioner of the filing and unique docket number of the petition.

(d) An interested person may submit comments to the Division of Dockets Management on a filed petition, which comments become part of the docket file. The comments are to specify the docket number of the petition and may support or oppose the petition in whole or in part. A request for alternative or different administrative action must be submitted as a separate petition.

(e)(1) The Commissioner shall, in accordance with paragraph (e)(2), rule upon each petition filed under paragraph (c) of this section, taking into consideration (i) available agency resources for the category of subject matter, (ii) the priority assigned to the petition considering both the category of subject matter involved and the overall work of the agency, and (iii) time requirements established by statute.

(2) Except as provided in paragraph (e)(4) of this section, the Commissioner shall furnish a response to each petitioner within 180 days of receipt of the petition. The response will either:

(i) Approve the petition, in which case the Commissioner shall concurrently take appropriate action (e.g., publication of a Federal Register notice) implementing the approval;

(ii) Deny the petition; or

(iii) Provide a tentative response, indicating why the agency has been unable to reach a decision on the petition, e.g., because of the existence of other agency priorities, or a need for additional information. The tentative response may also indicate the likely ultimate agency response, and may specify when a final response may be furnished.

(3) The Commissioner may grant or deny such a petition, in whole or in part, and may grant such other relief or take other action as the petition warrants. The petitioner is to be notified of the Commissioner’s decision. The decision will be placed in the public docket file and may also be in the form of a notice published in the Federal Register.

(4) The Commissioner shall furnish a response to each petitioner within 90 days of receipt of a petition filed under section 505(j)(2)(C) of the act. The response will either approve or disapprove the petition. Agency action on a petition shall be governed by 314.93 of this chapter.

(f) If a petition filed under paragraph (c) of this section requests the Commissioner to issue, amend, or revoke a regulation, 10.40 or 10.50 also apply.

(g) A petitioner may supplement, amend, or withdraw a petition without Agency approval and without prejudice to resubmission at any time until the Commissioner rules on the petition, unless the petition has been referred for a hearing under parts 12, 13, 14, or 15 of this chapter. After a ruling or referral, a petition may be supplemented, amended, or withdrawn only with the approval of the Commissioner. The Commissioner may approve withdrawal, with or without prejudice against resubmission of the petition.

(h) In reviewing a petition the Commissioner may use the following procedures:

(1) Conferences, meetings, discussions, and correspondence under 10.65.

(2) A hearing under parts 12, 13, 14, 15, or 16.

(3) A Federal Register notice requesting information and views.

(4) A proposal to issue, amend, or revoke a regulation, in accordance with 10.40 or 12.20.

(5) Any other specific public procedure established in this chapter and expressly applicable to the matter.

(i) The record of the administrative proceeding consists of the following:

(1) The petition, including all information on which it relies, filed by the Division of Dockets Management.

(2) All comments received on the petition, including all information submitted as a part of the comments.

(3) If the petition resulted in a proposal to issue, amend, or revoke a regulation, all of the documents specified in 10.40(g).

(4) The record, consisting of any transcripts, minutes of meetings, reports, Federal Register notices, and other documents resulting from the optional procedures specified in paragraph (h) of this section, except a transcript of a closed portion of a public advisory committee meeting.

(5) The Commissioner’s decision on the petition, including all information identified or filed by the Commissioner with the Division of Dockets Management as part of the record supporting the decision.

(6) All documents filed with the Division of Dockets Management under 10.65(h).

(7) If a petition for reconsideration or for a stay of action is filed under paragraph (j) of this section, the administrative record specified in 10.33(k) or 10.35(h).

(j) The administrative record specified in paragraph (i) of this section is the exclusive record for the Commissioner’s decision. The record of the administrative proceeding closes on the date of the Commissioner’s decision unless some other date is specified. Thereafter any interested person may submit a petition for reconsideration under 10.33 or a petition for stay of action under 10.35. A person who wishes to rely upon information or views not included in the administrative record shall submit them to the Commissioner with a new petition to modify the decision in accordance with this section.

(k) This section does not apply to the referral of a matter to a United States attorney for the initiation of court enforcement action and related correspondence, or to requests, suggestions, and recommendations made informally in routine correspondence received by FDA. Routine correspondence does not constitute a petition within the meaning of this section unless it purports to meet the requirements of this section. Action on routine correspondence does not constitute final administrative action subject to judicial review under 10.45.

(l) The Division of Dockets Management will maintain a chronological list of each petition filed under this section and 10.85, but not of petitions submitted elsewhere in the agency under 10.25(a)(1), showing:

(1) The docket number;

(2) The date the petition was filed by the Division of Dockets Management;

(3) The name of the petitioner;

(4) The subject matter involved; and

(5) The disposition of the petition.

[44 FR 22323, Apr. 13, 1979, as amended at 46 FR 8455, Jan. 27, 1981; 50 FR 16656, Apr. 26, 1985; 54 FR 9034, Mar. 3, 1989; 57 FR 17980, Apr. 28, 1992; 59 FR 14364, Mar. 28, 1994; 62 FR 40592, July 29, 1997; 66 FR 6467, Jan. 22, 2001; 66 FR 12848, Mar. 1, 2001; 78 FR 76749, Dec. 19, 2013]

Tamoxifen

A drug that is already out there and can help repair Myelin. We don’t have time to wait. I urge all to write to MS Foundation, FDA everyone and anyone. I don’t know about you, but I do not have time to wait, waste and waste away.  Please promote and sign.

Tamoxifen (brand name, Nolvadex), a widely used treatment for breast cancer, can also be used to treat myelin loss in patients with multiple sclerosis (MS), a new study suggests.

“The finding, by a team of researchers at the University of Cambridge, U.K., was published in a study titled “Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system” in the journal Scientific Reports.

Researchers used both  in vitro cultures and a mouse model with reduced levels of myelin to analyze how six existing drugs might effect the repair and recovery of cells able to produce myelin, called oligodendrocytes.”

Epipen

I do not understand why those of us with MS are not getting vocal abut the Epipen and drug costs. Why aren’t we getting out there and talking about our drug costs and our insane increases? As for me I have tried to get exact numbers and the best I could find was an NPR piece from over a year ago. Costs below, and we wonder why no cure in site.  We are a cash cow for Big Pharma the time to get our voices heard is now. Please join me!

DRUG DATE APPROVED INITIAL COST (IN 2013 DOLLARS) 2013 COST INCREASE
Interferon-β-1b (Betaseron) 7/23/1993 $18,591 $61,529 231.0%
Interferon-β-1a IM (Avonex) 5/17/1996 $12,951 $62,394 381.8%
Glatiramer acetate (Copaxone) 12/20/1996 $12,312 $59,158 380.5%
Interferon-β-1a SC (Rebif) 3/7/2002 $19,763 $66,394 236.0%
Natalizumab (Tysabri) 11/23/2004 $31,879 $64,233 101.5%
Interferon-β-1b (Extavia) 8/14/2009 $35,644 $51,427 44.3%
Fingolimod (Gilenya) 9/21/2010 $54,245 $63,806 17.6%
Teriflunomide (Aubagio) 9/12/2012 $48,349 $57,553 19.0%
Dimethyl fumarate (Tecfidera) 3/27/2013 $57,816 $63,315 9.5%

BIG F%%##

Has anyone tried to get the exact price of each and all MS drugs? I know I have, easier said then done. What is the value of my life? Do you remember the scene in It’s a Wonderful Life where Jimmy Stewart says, “I’m worth more dead than alive?”

The sad but true fact is we are better off sick than well. That way BF*&%# can keep making their money. Recent news says they are busy looking for a vaccine for JCV virus, that way if they can fix that more of us can take their drugs. Why not just look for a vaccine to cure MS? OH wait………no profit!!!